These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22587685)

  • 1. Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement.
    Arefi M; García JL; Peñarrubia MJ; Queizán JA; Hermosín L; López-Corral L; Megido M; Giraldo P; de las Heras N; Vanegas RJ; Gutiérrez NC; Hernández-Rivas JM
    Eur J Haematol; 2012 Jul; 89(1):37-41. PubMed ID: 22587685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
    Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
    N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders.
    Gallagher G; Horsman DE; Tsang P; Forrest DL
    Cancer Genet Cytogenet; 2008 Feb; 181(1):46-51. PubMed ID: 18262053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasms.
    Hidalgo-Curtis C; Apperley JF; Stark A; Jeng M; Gotlib J; Chase A; Cross NC; Grand FH
    Br J Haematol; 2010 Jan; 148(2):268-73. PubMed ID: 20085582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32).
    Levine RL; Wadleigh M; Sternberg DW; Wlodarska I; Galinsky I; Stone RM; DeAngelo DJ; Gilliland DG; Cools J
    Leukemia; 2005 Jan; 19(1):27-30. PubMed ID: 15496975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Philadelphia chromosome-negative myeloproliferative neoplasm with a novel platelet-derived growth factor receptor-β rearrangement responsive to imatinib.
    Cornfield D; Shah U; Cross N; Bennett C; Sun G
    J Clin Oncol; 2012 Mar; 30(9):e109-11. PubMed ID: 22331939
    [No Abstract]   [Full Text] [Related]  

  • 7. Congenital and childhood myeloproliferative disorders with eosinophilia responsive to imatinib.
    Abraham S; Salama M; Hancock J; Jacobsen J; Fluchel M
    Pediatr Blood Cancer; 2012 Nov; 59(5):928-9. PubMed ID: 22488677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia.
    Medves S; Duhoux FP; Ferrant A; Toffalini F; Ameye G; Libouton JM; Poirel HA; Demoulin JB
    Leukemia; 2010 May; 24(5):1052-5. PubMed ID: 20164854
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pediatric myeloid neoplasms associated with eosinophilia and platelet-derived growth factor receptor beta gene rearrangement: a case report and literature review].
    Zhang XY; Liu TF; Li CW; Li QH; Zhu XF
    Zhonghua Er Ke Za Zhi; 2018 Jan; 56(1):34-38. PubMed ID: 29342995
    [No Abstract]   [Full Text] [Related]  

  • 10. Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia.
    Winkelmann N; Hidalgo-Curtis C; Waghorn K; Score J; Dickinson H; Jack A; Ali S; Cross NC
    Leuk Lymphoma; 2013 Jul; 54(7):1527-31. PubMed ID: 23186533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.
    Gosenca D; Kellert B; Metzgeroth G; Haferlach C; Fabarius A; Schwaab J; Kneba M; Scheid C; Töpelt K; Erben P; Haferlach T; Cross NC; Hofmann WK; Seifarth W; Reiter A
    Genes Chromosomes Cancer; 2014 May; 53(5):411-21. PubMed ID: 24772479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2).
    Walz C; Haferlach C; Hänel A; Metzgeroth G; Erben P; Gosenca D; Hochhaus A; Cross NC; Reiter A
    Genes Chromosomes Cancer; 2009 Feb; 48(2):179-83. PubMed ID: 19006078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate.
    Rathe M; Kristensen TK; Møller MB; Carlsen NL
    Pediatr Blood Cancer; 2010 Oct; 55(4):730-2. PubMed ID: 20589620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.
    David M; Cross NC; Burgstaller S; Chase A; Curtis C; Dang R; Gardembas M; Goldman JM; Grand F; Hughes G; Huguet F; Lavender L; McArthur GA; Mahon FX; Massimini G; Melo J; Rousselot P; Russell-Jones RJ; Seymour JF; Smith G; Stark A; Waghorn K; Nikolova Z; Apperley JF
    Blood; 2007 Jan; 109(1):61-4. PubMed ID: 16960151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder.
    Vizmanos JL; Novo FJ; Román JP; Baxter EJ; Lahortiga I; Larráyoz MJ; Odero MD; Giraldo P; Calasanz MJ; Cross NC
    Cancer Res; 2004 Apr; 64(8):2673-6. PubMed ID: 15087377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): case report.
    Choi IK; Kim BS; Lee KA; Ryu S; Seo HY; Sul H; Choi JG; Sung HJ; Park KH; Yoon SY; Oh SC; Seo JH; Choi CW; Shin SW; Yoon SY; Cho Y; Kim YK; Kim YH; Kim JS
    Am J Hematol; 2004 Dec; 77(4):366-9. PubMed ID: 15551277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.
    Walz C; Metzgeroth G; Haferlach C; Schmitt-Graeff A; Fabarius A; Hagen V; Prümmer O; Rauh S; Hehlmann R; Hochhaus A; Cross NC; Reiter A
    Haematologica; 2007 Feb; 92(2):163-9. PubMed ID: 17296564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
    Patterer V; Schnittger S; Kern W; Haferlach T; Haferlach C
    Ann Hematol; 2013 Jun; 92(6):759-69. PubMed ID: 23400675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders.
    Cross NC; Reiter A
    Acta Haematol; 2008; 119(4):199-206. PubMed ID: 18566537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloid neoplasm with a novel cryptic PDGFRB rearrangement detected by next-generation sequencing.
    Zimmermann N; Nassiri M; Zhou J; Miller AM; Zhang S
    Cancer Genet; 2020 Jun; 244():55-59. PubMed ID: 32442889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.